3 Dividend Stocks to Buy Hand Over Fist in June
Written by Selena Maranjian for The Motley Fool -> Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well. UPS has turned away from Amazon.com and toward more profitable deliveries. The Schwab U.S. Dividend Equity ETF offers both div
Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well.
UPS has turned away from Amazon.com and toward more profitable deliveries.
The Schwab U.S. Dividend Equity ETF offers both dividend income and growth.
If you want to be a savvy investor, you should know what this table is telling you:
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
As it starkly shows, it's hard to beat healthy and growing dividend-paying stocks if you're looking to boost your wealth over time. Here, then, are three to consider.
Let's start with pharmaceutical giant Pfizer (NYSE: PFE) . It's a compelling dividend payer largely because of its dividend yield -- recently a fat 6.7%. That payout is hefty in large part because the stock has averaged annual losses of about 7% over the past three years. (It's up 17% over the past year, though, as of June 4.) When a stock's price falls, its dividend yield rises, so many high-yielders have been facing some kind of struggle.
A key challenge for Pfizer has been the patent protection expiration of some of its biggest sellers. That's an issue for every pharmaceutical company, and one which they typically tackle by having a pipeline filled with promising drugs in development -- and/or by acquiring such promising drugs from other companies. Pfizer is doing both .
